慢性腎臓病（CKD）治療薬の世界市場 2024-2028

概要

慢性腎臓病（CKD）治療薬市場は2023-2028年に38億1,000万米ドル、予測期間中のCAGRは4.77%で成長すると予測されます。

当レポートでは、慢性腎臓病（CKD）治療薬市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。世界のCKD有病率の上昇、世界のヘルスケア支出の増加、CKDの早期発見と診断の必要性に対する意識の高まりなどが市場を牽引しています。

本調査では、今後数年間における慢性腎臓病（CKD）治療薬市場の成長を促進する主な要因の1つとして、CKD治療薬の承認件数の増加を挙げています。また、CKD治療における精密医療の採用への注目の高まりとCKD治療における技術革新は、市場の大きな需要につながると見込まれています。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模

• 市場の定義
• 市場セグメント分析
• 市場規模 2023
• 市場の見通し 2023-2028

第4章 市場規模実績

• 慢性腎臓病（CKD）治療薬の世界市場 2018-2022
• 薬物クラスセグメント分析 2018-2022
• 投与経路セグメント分析 2018-2022
• 地域別セグメント分析 2018-2022
• 国別セグメント分析 2018-2022

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション薬剤クラス別

• 市場セグメント
• 比較薬剤クラス別
• エリスロポエチン刺激剤（ESA）：市場規模と予測 2023-2028
• カルシウム拮抗剤：市場規模と予測 2023-2028
• リン酸塩結合剤：市場規模と予測 2023-2028
• ACE阻害剤：市場規模と予測 2023-2028
• その他：市場規模と予測 2023-2028
• 市場機会薬剤クラス別

第7章 市場セグメンテーション：投与経路別

• 市場セグメント
• 比較：投与経路別
• オーラル：市場規模と予測 2023-2028
• 皮下：市場規模と予測 2023-2028
• 静脈内：市場規模と予測 2023-2028
• 市場機会：投与経路別

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• 北米：市場規模と予測 2023-2028
• 欧州：市場規模と予測 2023-2028
• アジア：市場規模と予測 2023-2028
• 世界のその他の地域：市場規模と予測 2023-2028
• 米国：市場規模と予測 2023-2028
• 中国：市場規模と予測 2023-2028
• ドイツ：市場規模と予測 2023-2028
• 英国：市場規模と予測 2023-2028
• インド：市場規模と予測 2023-2028
• 市場機会：地域情勢別

第10章 促進要因、課題、および動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• Abbott Laboratories
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• Bayer AG
• Biogen Inc.
• Boehringer Ingelheim International GmbH
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Horizon Therapeutics Plc
• Johnson and Johnson
• Novartis AG
• OPKO Health Inc.
• Pfizer Inc.
• Sanofi SA

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Drug Class
• Exhibits6: Executive Summary - Chart on Market Segmentation by Route of Administration
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits18: Historic Market Size - Data Table on global chronic kidney disease (ckd) drugs market 2018 - 2022 ($ billion)
• Exhibits19: Historic Market Size - Drug Class Segment 2018 - 2022 ($ billion)
• Exhibits20: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ billion)
• Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
• Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
• Exhibits23: Five forces analysis - Comparison between 2023 and 2028
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
• Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
• Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
• Exhibits29: Chart on Market condition - Five forces 2023 and 2028
• Exhibits30: Chart on Drug Class - Market share 2023-2028 (%)
• Exhibits31: Data Table on Drug Class - Market share 2023-2028 (%)
• Exhibits32: Chart on Comparison by Drug Class
• Exhibits33: Data Table on Comparison by Drug Class
• Exhibits34: Chart on Erythropoietin stimulating agents (ESAs) - Market size and forecast 2023-2028 ($ billion)
• Exhibits35: Data Table on Erythropoietin stimulating agents (ESAs) - Market size and forecast 2023-2028 ($ billion)
• Exhibits36: Chart on Erythropoietin stimulating agents (ESAs) - Year-over-year growth 2023-2028 (%)
• Exhibits37: Data Table on Erythropoietin stimulating agents (ESAs) - Year-over-year growth 2023-2028 (%)
• Exhibits38: Chart on Calcium channel blockers - Market size and forecast 2023-2028 ($ billion)
• Exhibits39: Data Table on Calcium channel blockers - Market size and forecast 2023-2028 ($ billion)
• Exhibits40: Chart on Calcium channel blockers - Year-over-year growth 2023-2028 (%)
• Exhibits41: Data Table on Calcium channel blockers - Year-over-year growth 2023-2028 (%)
• Exhibits42: Chart on Phosphate binders - Market size and forecast 2023-2028 ($ billion)
• Exhibits43: Data Table on Phosphate binders - Market size and forecast 2023-2028 ($ billion)
• Exhibits44: Chart on Phosphate binders - Year-over-year growth 2023-2028 (%)
• Exhibits45: Data Table on Phosphate binders - Year-over-year growth 2023-2028 (%)
• Exhibits46: Chart on ACE inhibitors - Market size and forecast 2023-2028 ($ billion)
• Exhibits47: Data Table on ACE inhibitors - Market size and forecast 2023-2028 ($ billion)
• Exhibits48: Chart on ACE inhibitors - Year-over-year growth 2023-2028 (%)
• Exhibits49: Data Table on ACE inhibitors - Year-over-year growth 2023-2028 (%)
• Exhibits50: Chart on Others - Market size and forecast 2023-2028 ($ billion)
• Exhibits51: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
• Exhibits52: Chart on Others - Year-over-year growth 2023-2028 (%)
• Exhibits53: Data Table on Others - Year-over-year growth 2023-2028 (%)
• Exhibits54: Market opportunity by Drug Class ($ billion)
• Exhibits55: Data Table on Market opportunity by Drug Class ($ billion)
• Exhibits56: Chart on Route of Administration - Market share 2023-2028 (%)
• Exhibits57: Data Table on Route of Administration - Market share 2023-2028 (%)
• Exhibits58: Chart on Comparison by Route of Administration
• Exhibits59: Data Table on Comparison by Route of Administration
• Exhibits60: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
• Exhibits61: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
• Exhibits62: Chart on Oral - Year-over-year growth 2023-2028 (%)
• Exhibits63: Data Table on Oral - Year-over-year growth 2023-2028 (%)
• Exhibits64: Chart on Subcutaneous - Market size and forecast 2023-2028 ($ billion)
• Exhibits65: Data Table on Subcutaneous - Market size and forecast 2023-2028 ($ billion)
• Exhibits66: Chart on Subcutaneous - Year-over-year growth 2023-2028 (%)
• Exhibits67: Data Table on Subcutaneous - Year-over-year growth 2023-2028 (%)
• Exhibits68: Chart on Intravenous - Market size and forecast 2023-2028 ($ billion)
• Exhibits69: Data Table on Intravenous - Market size and forecast 2023-2028 ($ billion)
• Exhibits70: Chart on Intravenous - Year-over-year growth 2023-2028 (%)
• Exhibits71: Data Table on Intravenous - Year-over-year growth 2023-2028 (%)
• Exhibits72: Market opportunity by Route of Administration ($ billion)
• Exhibits73: Data Table on Market opportunity by Route of Administration ($ billion)
• Exhibits74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits75: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits76: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits77: Chart on Geographic comparison
• Exhibits78: Data Table on Geographic comparison
• Exhibits79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibits80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibits81: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibits82: Data Table on North America - Year-over-year growth 2023-2028 (%)
• Exhibits83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibits84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibits85: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibits88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibits89: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits90: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibits92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibits93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits95: Chart on US - Market size and forecast 2023-2028 ($ billion)
• Exhibits96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
• Exhibits97: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibits98: Data Table on US - Year-over-year growth 2023-2028 (%)
• Exhibits99: Chart on China - Market size and forecast 2023-2028 ($ billion)
• Exhibits100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
• Exhibits101: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibits102: Data Table on China - Year-over-year growth 2023-2028 (%)
• Exhibits103: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibits104: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibits105: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits106: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits107: Chart on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibits108: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibits109: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibits110: Data Table on UK - Year-over-year growth 2023-2028 (%)
• Exhibits111: Chart on India - Market size and forecast 2023-2028 ($ billion)
• Exhibits112: Data Table on India - Market size and forecast 2023-2028 ($ billion)
• Exhibits113: Chart on India - Year-over-year growth 2023-2028 (%)
• Exhibits114: Data Table on India - Year-over-year growth 2023-2028 (%)
• Exhibits115: Market opportunity By Geographical Landscape ($ billion)
• Exhibits116: Data Tables on Market opportunity By Geographical Landscape ($ billion)
• Exhibits117: Impact of drivers and challenges in 2023 and 2028
• Exhibits118: Overview on Criticality of inputs and Factors of differentiation
• Exhibits119: Overview on factors of disruption
• Exhibits120: Impact of key risks on business
• Exhibits121: Vendors covered
• Exhibits122: Matrix on vendor position and classification
• Exhibits123: Abbott Laboratories - Overview
• Exhibits124: Abbott Laboratories - Business segments
• Exhibits125: Abbott Laboratories - Key news
• Exhibits126: Abbott Laboratories - Key offerings
• Exhibits127: Abbott Laboratories - Segment focus
• Exhibits128: AbbVie Inc. - Overview
• Exhibits129: AbbVie Inc. - Product / Service
• Exhibits130: AbbVie Inc. - Key news
• Exhibits131: AbbVie Inc. - Key offerings
• Exhibits132: Amgen Inc. - Overview
• Exhibits133: Amgen Inc. - Product / Service
• Exhibits134: Amgen Inc. - Key offerings
• Exhibits135: AstraZeneca Plc - Overview
• Exhibits136: AstraZeneca Plc - Product / Service
• Exhibits137: AstraZeneca Plc - Key news
• Exhibits138: AstraZeneca Plc - Key offerings
• Exhibits139: Bayer AG - Overview
• Exhibits140: Bayer AG - Business segments
• Exhibits141: Bayer AG - Key news
• Exhibits142: Bayer AG - Key offerings
• Exhibits143: Bayer AG - Segment focus
• Exhibits144: Biogen Inc. - Overview
• Exhibits145: Biogen Inc. - Product / Service
• Exhibits146: Biogen Inc. - Key offerings
• Exhibits147: Boehringer Ingelheim International GmbH - Overview
• Exhibits148: Boehringer Ingelheim International GmbH - Business segments
• Exhibits149: Boehringer Ingelheim International GmbH - Key news
• Exhibits150: Boehringer Ingelheim International GmbH - Key offerings
• Exhibits151: Boehringer Ingelheim International GmbH - Segment focus
• Exhibits152: Eli Lilly and Co. - Overview
• Exhibits153: Eli Lilly and Co. - Product / Service
• Exhibits154: Eli Lilly and Co. - Key news
• Exhibits155: Eli Lilly and Co. - Key offerings
• Exhibits156: F. Hoffmann La Roche Ltd. - Overview
• Exhibits157: F. Hoffmann La Roche Ltd. - Business segments
• Exhibits158: F. Hoffmann La Roche Ltd. - Key news
• Exhibits159: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibits160: F. Hoffmann La Roche Ltd. - Segment focus
• Exhibits161: Horizon Therapeutics Plc - Overview
• Exhibits162: Horizon Therapeutics Plc - Business segments
• Exhibits163: Horizon Therapeutics Plc - Key news
• Exhibits164: Horizon Therapeutics Plc - Key offerings
• Exhibits165: Horizon Therapeutics Plc - Segment focus
• Exhibits166: Johnson and Johnson - Overview
• Exhibits167: Johnson and Johnson - Business segments
• Exhibits168: Johnson and Johnson - Key news
• Exhibits169: Johnson and Johnson - Key offerings
• Exhibits170: Johnson and Johnson - Segment focus
• Exhibits171: Novartis AG - Overview
• Exhibits172: Novartis AG - Business segments
• Exhibits173: Novartis AG - Key offerings
• Exhibits174: Novartis AG - Segment focus
• Exhibits175: OPKO Health Inc. - Overview
• Exhibits176: OPKO Health Inc. - Business segments
• Exhibits177: OPKO Health Inc. - Key offerings
• Exhibits178: OPKO Health Inc. - Segment focus
• Exhibits179: Pfizer Inc. - Overview
• Exhibits180: Pfizer Inc. - Product / Service
• Exhibits181: Pfizer Inc. - Key news
• Exhibits182: Pfizer Inc. - Key offerings
• Exhibits183: Sanofi SA - Overview
• Exhibits184: Sanofi SA - Business segments
• Exhibits185: Sanofi SA - Key news
• Exhibits186: Sanofi SA - Key offerings
• Exhibits187: Sanofi SA - Segment focus
• Exhibits188: Inclusions checklist
• Exhibits189: Exclusions checklist
• Exhibits190: Currency conversion rates for US$
• Exhibits191: Research methodology
• Exhibits192: Validation techniques employed for market sizing
• Exhibits193: Information sources
• Exhibits194: List of abbreviations

Abstract

The chronic kidney disease (CKD) drugs market is forecasted to grow by USD 3.81 bn during 2023-2028, accelerating at a CAGR of 4.77% during the forecast period. The report on the chronic kidney disease (CKD) drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of CKD globally, increase in healthcare expenditure globally, and growing awareness about need for early detection and diagnosis of CKD.

Technavio's chronic kidney disease (CKD) drugs market is segmented as below:

By Drug Class

• Erythropoietin stimulating agents
• Calcium channel blockers
• Phosphate binders
• ACE inhibitors
• Others

By Route Of Administration

• Oral
• Subcutaneous
• Intravenous

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the growing number of drug approvals for CKD treatment as one of the prime reasons driving the chronic kidney disease (CKD) drugs market growth during the next few years. Also, rising focus on adoption of precision medicine for CKD treatment and technological innovations in CKD treatment will lead to sizable demand in the market.

The report on the chronic kidney disease (CKD) drugs market covers the following areas:

• Chronic kidney disease (CKD) drugs market sizing
• Chronic kidney disease (CKD) drugs market forecast
• Chronic kidney disease (CKD) drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic kidney disease (CKD) drugs market vendors that include Abbott Laboratories, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Cara Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., FibroGen Inc., Horizon Therapeutics Plc, Johnson and Johnson, Kissei Pharmaceutical Co. Ltd., Novartis AG, OPKO Health Inc., Pfizer Inc., Pharmacosmos AS, Rockwell Medical Inc., Sanofi SA, Shield Therapeutics plc, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Xenetic Biosciences Inc., Zydus Lifesciences Ltd., Ardelyx Inc., and Aurinia Pharmaceuticals Inc.. Also, the chronic kidney disease (CKD) drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global chronic kidney disease (CKD) drugs market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global chronic kidney disease (ckd) drugs market 2018 - 2022 ($ billion)
• 4.2 Drug Class Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Drug Class Segment 2018 - 2022 ($ billion)
• 4.3 Route of Administration Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ billion)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Drug Class

• 6.1 Market segments
• Exhibit 30: Chart on Drug Class - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Drug Class - Market share 2023-2028 (%)
• 6.2 Comparison by Drug Class
• Exhibit 32: Chart on Comparison by Drug Class
• Exhibit 33: Data Table on Comparison by Drug Class
• 6.3 Erythropoietin stimulating agents (ESAs) - Market size and forecast 2023-2028
• Exhibit 34: Chart on Erythropoietin stimulating agents (ESAs) - Market size and forecast 2023-2028 ($ billion)
• Exhibit 35: Data Table on Erythropoietin stimulating agents (ESAs) - Market size and forecast 2023-2028 ($ billion)
• Exhibit 36: Chart on Erythropoietin stimulating agents (ESAs) - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Erythropoietin stimulating agents (ESAs) - Year-over-year growth 2023-2028 (%)
• 6.4 Calcium channel blockers - Market size and forecast 2023-2028
• Exhibit 38: Chart on Calcium channel blockers - Market size and forecast 2023-2028 ($ billion)
• Exhibit 39: Data Table on Calcium channel blockers - Market size and forecast 2023-2028 ($ billion)
• Exhibit 40: Chart on Calcium channel blockers - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Calcium channel blockers - Year-over-year growth 2023-2028 (%)
• 6.5 Phosphate binders - Market size and forecast 2023-2028
• Exhibit 42: Chart on Phosphate binders - Market size and forecast 2023-2028 ($ billion)
• Exhibit 43: Data Table on Phosphate binders - Market size and forecast 2023-2028 ($ billion)
• Exhibit 44: Chart on Phosphate binders - Year-over-year growth 2023-2028 (%)
• Exhibit 45: Data Table on Phosphate binders - Year-over-year growth 2023-2028 (%)
• 6.6 ACE inhibitors - Market size and forecast 2023-2028
• Exhibit 46: Chart on ACE inhibitors - Market size and forecast 2023-2028 ($ billion)
• Exhibit 47: Data Table on ACE inhibitors - Market size and forecast 2023-2028 ($ billion)
• Exhibit 48: Chart on ACE inhibitors - Year-over-year growth 2023-2028 (%)
• Exhibit 49: Data Table on ACE inhibitors - Year-over-year growth 2023-2028 (%)
• 6.7 Others - Market size and forecast 2023-2028
• Exhibit 50: Chart on Others - Market size and forecast 2023-2028 ($ billion)
• Exhibit 51: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
• Exhibit 52: Chart on Others - Year-over-year growth 2023-2028 (%)
• Exhibit 53: Data Table on Others - Year-over-year growth 2023-2028 (%)
• 6.8 Market opportunity by Drug Class
• Exhibit 54: Market opportunity by Drug Class ($ billion)
• Exhibit 55: Data Table on Market opportunity by Drug Class ($ billion)

7 Market Segmentation by Route of Administration

• 7.1 Market segments
• Exhibit 56: Chart on Route of Administration - Market share 2023-2028 (%)
• Exhibit 57: Data Table on Route of Administration - Market share 2023-2028 (%)
• 7.2 Comparison by Route of Administration
• Exhibit 58: Chart on Comparison by Route of Administration
• Exhibit 59: Data Table on Comparison by Route of Administration
• 7.3 Oral - Market size and forecast 2023-2028
• Exhibit 60: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
• Exhibit 61: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
• Exhibit 62: Chart on Oral - Year-over-year growth 2023-2028 (%)
• Exhibit 63: Data Table on Oral - Year-over-year growth 2023-2028 (%)
• 7.4 Subcutaneous - Market size and forecast 2023-2028
• Exhibit 64: Chart on Subcutaneous - Market size and forecast 2023-2028 ($ billion)
• Exhibit 65: Data Table on Subcutaneous - Market size and forecast 2023-2028 ($ billion)
• Exhibit 66: Chart on Subcutaneous - Year-over-year growth 2023-2028 (%)
• Exhibit 67: Data Table on Subcutaneous - Year-over-year growth 2023-2028 (%)
• 7.5 Intravenous - Market size and forecast 2023-2028
• Exhibit 68: Chart on Intravenous - Market size and forecast 2023-2028 ($ billion)
• Exhibit 69: Data Table on Intravenous - Market size and forecast 2023-2028 ($ billion)
• Exhibit 70: Chart on Intravenous - Year-over-year growth 2023-2028 (%)
• Exhibit 71: Data Table on Intravenous - Year-over-year growth 2023-2028 (%)
• 7.6 Market opportunity by Route of Administration
• Exhibit 72: Market opportunity by Route of Administration ($ billion)
• Exhibit 73: Data Table on Market opportunity by Route of Administration ($ billion)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 75: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 76: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 77: Chart on Geographic comparison
• Exhibit 78: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibit 80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
• Exhibit 81: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibit 84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
• Exhibit 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibit 88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
• Exhibit 89: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
• Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 95: Chart on US - Market size and forecast 2023-2028 ($ billion)
• Exhibit 96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
• Exhibit 97: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 China - Market size and forecast 2023-2028
• Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
• Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
• Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.9 Germany - Market size and forecast 2023-2028
• Exhibit 103: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibit 104: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
• Exhibit 105: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 106: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.10 UK - Market size and forecast 2023-2028
• Exhibit 107: Chart on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibit 108: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
• Exhibit 109: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 110: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.11 India - Market size and forecast 2023-2028
• Exhibit 111: Chart on India - Market size and forecast 2023-2028 ($ billion)
• Exhibit 112: Data Table on India - Market size and forecast 2023-2028 ($ billion)
• Exhibit 113: Chart on India - Year-over-year growth 2023-2028 (%)
• Exhibit 114: Data Table on India - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 115: Market opportunity By Geographical Landscape ($ billion)
• Exhibit 116: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 117: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 118: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 119: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 120: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 121: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 122: Matrix on vendor position and classification
• 12.3 Abbott Laboratories
• Exhibit 123: Abbott Laboratories - Overview
• Exhibit 124: Abbott Laboratories - Business segments
• Exhibit 125: Abbott Laboratories - Key news
• Exhibit 126: Abbott Laboratories - Key offerings
• Exhibit 127: Abbott Laboratories - Segment focus
• 12.4 AbbVie Inc.
• Exhibit 128: AbbVie Inc. - Overview
• Exhibit 129: AbbVie Inc. - Product / Service
• Exhibit 130: AbbVie Inc. - Key news
• Exhibit 131: AbbVie Inc. - Key offerings
• 12.5 Amgen Inc.
• Exhibit 132: Amgen Inc. - Overview
• Exhibit 133: Amgen Inc. - Product / Service
• Exhibit 134: Amgen Inc. - Key offerings
• 12.6 AstraZeneca Plc
• Exhibit 135: AstraZeneca Plc - Overview
• Exhibit 136: AstraZeneca Plc - Product / Service
• Exhibit 137: AstraZeneca Plc - Key news
• Exhibit 138: AstraZeneca Plc - Key offerings
• 12.7 Bayer AG
• Exhibit 139: Bayer AG - Overview
• Exhibit 140: Bayer AG - Business segments
• Exhibit 141: Bayer AG - Key news
• Exhibit 142: Bayer AG - Key offerings
• Exhibit 143: Bayer AG - Segment focus
• 12.8 Biogen Inc.
• Exhibit 144: Biogen Inc. - Overview
• Exhibit 145: Biogen Inc. - Product / Service
• Exhibit 146: Biogen Inc. - Key offerings
• 12.9 Boehringer Ingelheim International GmbH
• Exhibit 147: Boehringer Ingelheim International GmbH - Overview
• Exhibit 148: Boehringer Ingelheim International GmbH - Business segments
• Exhibit 149: Boehringer Ingelheim International GmbH - Key news
• Exhibit 150: Boehringer Ingelheim International GmbH - Key offerings
• Exhibit 151: Boehringer Ingelheim International GmbH - Segment focus
• 12.10 Eli Lilly and Co.
• Exhibit 152: Eli Lilly and Co. - Overview
• Exhibit 153: Eli Lilly and Co. - Product / Service
• Exhibit 154: Eli Lilly and Co. - Key news
• Exhibit 155: Eli Lilly and Co. - Key offerings
• 12.11 F. Hoffmann La Roche Ltd.
• Exhibit 156: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 157: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 158: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 159: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 160: F. Hoffmann La Roche Ltd. - Segment focus
• 12.12 Horizon Therapeutics Plc
• Exhibit 161: Horizon Therapeutics Plc - Overview
• Exhibit 162: Horizon Therapeutics Plc - Business segments
• Exhibit 163: Horizon Therapeutics Plc - Key news
• Exhibit 164: Horizon Therapeutics Plc - Key offerings
• Exhibit 165: Horizon Therapeutics Plc - Segment focus
• 12.13 Johnson and Johnson
• Exhibit 166: Johnson and Johnson - Overview
• Exhibit 167: Johnson and Johnson - Business segments
• Exhibit 168: Johnson and Johnson - Key news
• Exhibit 169: Johnson and Johnson - Key offerings
• Exhibit 170: Johnson and Johnson - Segment focus
• 12.14 Novartis AG
• Exhibit 171: Novartis AG - Overview
• Exhibit 172: Novartis AG - Business segments
• Exhibit 173: Novartis AG - Key offerings
• Exhibit 174: Novartis AG - Segment focus
• 12.15 OPKO Health Inc.
• Exhibit 175: OPKO Health Inc. - Overview
• Exhibit 176: OPKO Health Inc. - Business segments
• Exhibit 177: OPKO Health Inc. - Key offerings
• Exhibit 178: OPKO Health Inc. - Segment focus
• 12.16 Pfizer Inc.
• Exhibit 179: Pfizer Inc. - Overview
• Exhibit 180: Pfizer Inc. - Product / Service
• Exhibit 181: Pfizer Inc. - Key news
• Exhibit 182: Pfizer Inc. - Key offerings
• 12.17 Sanofi SA
• Exhibit 183: Sanofi SA - Overview
• Exhibit 184: Sanofi SA - Business segments
• Exhibit 185: Sanofi SA - Key news
• Exhibit 186: Sanofi SA - Key offerings
• Exhibit 187: Sanofi SA - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 188: Inclusions checklist
• Exhibit 189: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 190: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 191: Research methodology
• Exhibit 192: Validation techniques employed for market sizing
• Exhibit 193: Information sources
• 13.5 List of abbreviations
• Exhibit 194: List of abbreviations